BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 34012921)

  • 1. Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia.
    van Gils N; Denkers F; Smit L
    Front Oncol; 2021; 11():659253. PubMed ID: 34012921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters.
    van Gils N; Verhagen HJMP; Broux M; Martiáñez T; Denkers F; Vermue E; Rutten A; Csikós T; Demeyer S; Çil M; Al M; Cools J; Janssen JJWM; Ossenkoppele GJ; Menezes RX; Smit L
    iScience; 2022 Sep; 25(9):105013. PubMed ID: 36097617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?
    Martiáñez Canales T; de Leeuw DC; Vermue E; Ossenkoppele GJ; Smit L
    Cancers (Basel); 2017 Jun; 9(7):. PubMed ID: 28665351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection.
    Srinivasan Rajsri K; Roy N; Chakraborty S
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convergent epigenetic evolution drives relapse in acute myeloid leukemia.
    Nuno K; Azizi A; Koehnke T; Lareau C; Ediriwickrema A; Corces MR; Satpathy AT; Majeti R
    Elife; 2024 Apr; 13():. PubMed ID: 38647535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
    Bernardi M; Ferrara F; Carrabba MG; Mastaglio S; Lorentino F; Vago L; Ciceri F
    Front Oncol; 2022; 12():890871. PubMed ID: 35924144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication.
    Hansen Q; Bachas C; Smit L; Cloos J
    Cancer Drug Resist; 2022; 5(2):344-367. PubMed ID: 35800375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Leukemic Target with a Thousand Faces: The Mitochondria.
    Maffeo B; Panuzzo C; Moraca A; Cilloni D
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemic stem cells and therapy resistance in acute myeloid leukemia.
    Stelmach P; Trumpp A
    Haematologica; 2023 Feb; 108(2):353-366. PubMed ID: 36722405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
    DiNardo CD; Tiong IS; Quaglieri A; MacRaild S; Loghavi S; Brown FC; Thijssen R; Pomilio G; Ivey A; Salmon JM; Glytsou C; Fleming SA; Zhang Q; Ma H; Patel KP; Kornblau SM; Xu Z; Chua CC; Chen X; Blombery P; Flensburg C; Cummings N; Aifantis I; Kantarjian H; Huang DCS; Roberts AW; Majewski IJ; Konopleva M; Wei AH
    Blood; 2020 Mar; 135(11):791-803. PubMed ID: 31932844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells.
    Li F; Gao C; Li X; Wang J; Zhao Y; Ke Y; Liu Y; Liu HM; Hu Z; Wei L; Chen ZS
    Front Pharmacol; 2022; 13():1001552. PubMed ID: 36133825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable Residual Disease in High-Risk Acute Myeloid Leukemia.
    Cluzeau T; Lemoli RM; McCloskey J; Cooper T
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.
    Niu J; Peng D; Liu L
    Front Oncol; 2022; 12():896426. PubMed ID: 35865470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
    Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
    Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia.
    Reichle A; Rothe G; Krause S; Zaiss M; Ullrich H; Schmitz G; Andreesen R
    Leukemia; 1999 Aug; 13(8):1227-34. PubMed ID: 10450751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
    DeAngelo DJ; Stein EM; Ravandi F
    Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.
    Sachs K; Sarver AL; Noble-Orcutt KE; LaRue RS; Antony ML; Chang D; Lee Y; Navis CM; Hillesheim AL; Nykaza IR; Ha NA; Hansen CJ; Karadag FK; Bergerson RJ; Verneris MR; Meredith MM; Schomaker ML; Linden MA; Myers CL; Largaespada DA; Sachs Z
    Cancer Res; 2020 Feb; 80(3):458-470. PubMed ID: 31784425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
    San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
    Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.